Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer

A Phase 2 Study of LY573636-Sodium Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer

The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment.

Inclusion Criteria:

• Diagnosis of metastatic non-small-cell lung cancer
• At least 18 years of age
• Have received 2 previous treatment regimens for metastatic non-small-cell lung cancer

Exclusion Criteria:

• Serious pre-existing medical conditions
• Previous cancer (except skin cancer, excluding melanoma)
• Have received 3 or more previous treatment regimens for metastatic non- small-cell lung cancer
• Active treatment with Coumadin